An interventional study of Smartphone restriction in Headache Disorders, sponsored by All India Institute of Medical Sciences. Recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by All India Institute of Medical Sciences · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to study smartphone use restriction as a treatment modality in patients of primary headache. The main question[s] it aims to answer are:
The smartphone users may further be classified into low and high smartphone users depending upon the smartphone addiction questionnaire (SAQ) (appendix 1) usage score. SUs with 0-1 score on the SAQ were further grouped into low SUs, and patients with score ≥1 were grouped into high SUs. To create a homogenous group, only patients with high SU will be randomized to standard treatment (Arm C) and intervention group (Arm D).
Participants will be asked about their smartphone usage, and if found eligible, there will be a run-in period of 4 weeks after which they will be randomized to the intervention (smartphone restriction) or comparison group (no restriction recommended)
Study description:
Patients/participants:
Willing and consenting to participate in the study. Patients will be first asked about their smartphone use.
If they use smartphone their use will be recorded over the study period in terms of:
o Screen use: Social network/testing/gaming/surfing/reading/music/video
Patients with headache with history of high smartphone use will be randomized into restriction and no-restriction arm.
Restriction method:
In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
Comparison:
In the non-intervention group only the smartphone usage data will be collected in the study period. The non-smartphone users will be as another control arm.
Outcome:
Primary:
The number of times the patient is using acute pain medications for headache per month, within three months after initiation of study period.
Secondary:
Timeline of measuring outcome:
The follow up will be over a period of 20 weeks after screening eligibility and 16 weeks after randomization. The patient will maintain a headache diary in which he/she will enter the number of times they needed to take rescue medication.
145 studies on the registry are indexed under Headache Disorders; 37 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 98 interventional studies indexed under Headache Disorders.
Browse Headache Disorders studies →All India Institute of Medical Sciences is the lead sponsor of 27 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with headache with history of high smartphone use will be randomized into restriction and no-restriction arm. Restriction method: In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
Behavioral: Smartphone restriction
Comparison: In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. In the non-intervention group only the smartphone usage data will be collected in the study period. The non-smartphone users will be as another control arm.
The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
The pill burden for abortive treatment
The number of times the patient is using acute pain medications for headache in one month
Time frame: three months after initiation of study period
Headache frequency
The frequency of headache over a period of one month, three months after the initiation of study period in the intervention versus control group.
Time frame: One and three months
Number of prophylactic medication
The number of prophylaxis medications being taken three months after the initiation of study period in the intervention versus control group.
Time frame: Three months
Plan to share: Yes — Anonymized data will be shared on reasonable request
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After the completion of the publication for six months
Access criteria: Shared on individual request
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Sep 2026, 35 months after the start.
Of 41 non-industry interventional studies with no phase under Headache Disorders, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 35 months is above that.
Counting every sponsor, half of 43 studies reached it within 20 months; a quarter within 7 and three quarters within 42.
Completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Dec 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
All India Institute of Medical Sciences